All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Brought to you by

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

Types Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

Multiple Myeloma Types

2021-07-12T08:59:07.000Z

Evaluating the addition of elotuzumab to KRd by MRD assessment: the future of MRD-guided treatment?

By Becky Gribbell, Stephanie de Chalus, Maria Kasimati, Erika Roa

Featured

Ben Derman

Jul 12, 2021

Video series

Monitoring response in MM

5:9

Evaluating the addition of elotuzumab to KRd by MRD assessment: the future...

Ben Derman

2

3:19

How can MRD kinetics assessment help with treatment decisions during...

Bruno Paiva

3

3:38

What are the challenges and possibilities of ctDNA to monitor response and...

Parameswaran Hari

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Benjamin Derman, The University of Chicago, Chicago, US. We asked, What is the future of MRD-guided treatment?

Adding a monoclonal antibody to triple induction therapy in patients with multiple myeloma intending to undergo transplantation can achieve high overall response rates. In this video, Derman discusses a study investigating the impact of the addition of elotuzumab to KRd (carfilzomib + lenalidomide + dexamethasone) in managing complete response rates and/or MRD negativity rates regardless of transplant eligibility and high-risk cytogenetics.